Clinical Innovation Partnerships 2019

11 - 12 September, 2019

Hotel Palace, Berlin

44 (0) 20 7368 9836

Catherine Mela, Head of Clinical Sample Science at AstraZeneca
AstraZeneca Logo

Catherine Mela

Head of Clinical Sample Science

Check out the incredible speaker line-up to see who will be joining Catherine.

Download The Latest Agenda

Conference day two – Thursday 12 September 2019

Tuesday, November 12th, 2019

9:00 AM OPENING KEYNOTE - Modernising your clinical trials: How can you change your organisational structure to focus on real world evidence, remove barriers and deliver studies faster?

• How do you need to change your organisational structure to achieve modernisation?
• How can you convince regulators to have seamless evidence generation leading to real world evidence faster?
• How will vendors (central labs specifically) need to modernize to come with pharma on this journey?
• How will a new org structure remove barriers?

12:20 PM DRILL DOWN ROUND TABLES - How can you use clinical trials technologies to reduce trial time and costs, improve quality and provide a better patient experience?

1.       eTMF  Jeff Pilot, Senior Clinical Project Manager, Norgine
2.       Clinical Trials Platforms
3.       Translations
4.       Virtual Clinical Trials Raphaele Mary, Former Director of Capability & Strategy - Central Clinical Services, BMS
5.       Data
6.       AI & Blockchain
7.       ePRO
8.       eCRF
9.       CTMS
10.   IRS Almac (representative to be confirmed)
11.   Innovation Partnerships & Patient Engagement Catherine Mela, Director Clinical Sample & Bioanalytical Sciences, AstraZeneca
12.   Procurement

4:40 PM OXFORD STYLE DEBATE - Risk-sharing models are the best way to lower trial costs – FOR & AGAINST

FOR – 
•What are the benefits of new risk sharing relationship management models?
•How you can get more out of your CRO within a more flexible, mature and collaborative relationship?
•How can you maintain regulatory compliance and appropriate oversight within a risk-sharing relationship? 
•What negative financial impact might affect pharma’s ability to research and produce new drugs?

Our Sponsors: